Preclinical studies demonstrate that antagonism or genetic deletion of the C3aR confers neuroprotection in experimental stroke models—by reducing infarct volume, edema, neuroinflammation, and preserving BBB integrity—but translational challenges remain significant [20]. This evidence concerns the gene C3AR1 and Stroke.